Advertisement


Sumanta K. Pal, MD, on RCC: Results From Two Clinical Trials

2018 Genitourinary Cancers Symposium

Advertisement

Sumanta K. Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase III study findings from IMmotion151, which looked at atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (RCC), and results from a safety and efficacy trial of axitinib in combination with pembrolizumab with advanced RCC (Abstracts 578 & 579).



Related Videos

Kidney Cancer

Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).

Prostate Cancer

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Nicholas D. James, MBBS, PhD, of University Hospitals Birmingham NHS Foundation Trust, discusses study findings on the addition of docetaxel to first-line hormone therapy in prostate cancer, an analysis focusing on cost-effectiveness and long-term and quality-adjusted survival (Abstract 162).

Bladder Cancer

John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial

John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radiation plus gemcitabine for patients with muscle-invasive bladder cancer (Abstract 408).

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Results From the CheckMate 032 Trial

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses longer-term efficacy and safety findings on nivolumab monotherapy in metastatic urothelial carcinoma (Abstract 414).

Prostate Cancer
Immunotherapy

Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results

Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).

Advertisement

Advertisement




Advertisement